S. R. Park

Learn More
This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetuximab 400 mg m(-2) at week 1 and 250 mg m(-2) weekly(More)
The current treatment for metastatic gastric cancer (MGC) consists of cisplatin and/or fluorouracil (5-FU) based combination chemotherapy, but cisplatin-based regimens are associated with considerable toxicity. We evaluated the efficacy and safety of a noncisplatin-, non-5-FU-containing regimen, docetaxel/irinotecan in MGC. Chemo-naive patients with MGC(More)
We have performed high resolution angle-resolved photoemission (ARPES) studies on electron-doped cuprate superconductors Sm2-xCexCuO4 (x=0.10, 0.15, 0.18), Nd2-xCexCuO4 (x=0.15), and Eu2-xCexCuO4 (x=0.15). Imaginary parts of the electron removal self energy show steplike features due to an electron-bosonic mode coupling. The steplike feature is seen along(More)
Existing FPGAs have fairly simple and inefficient configuration mechanisms due to the relative infrequency of re-configuration. However a large class of dynamically config-urable architectures for DSP and communications can benefit from special-purpose configuration mechanisms which allow significant savings in configuration speed, power and memory. Light(More)
BACKGROUND We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin. METHODS Among MGC patients (n=108), who received S-1 (40 mg m(-2)(More)
BACKGROUND PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study evaluated the efficacy and safety of single agent PEP02 compared with irinotecan or docetaxel in the second-line treatment of advanced oesophago-gastric (OG) cancer. PATIENTS AND METHODS Patients with locally advanced/metastatic(More)
BACKGROUND The aim of this study was to investigate the efficacy and safety of S-1/irinotecan/oxaliplatin (TIROX) in metastatic gastric cancer (MGC) and the association between treatment outcome and uridine diphosphate-glucuronosyltransferase (UGT) 1A polymorphisms. PATIENTS AND METHODS Patients with previously untreated MGC received S-1 40 mg/m(2) b.i.d.(More)
We propose that existence of local orbital angular momentum (OAM) on the surfaces of high-Z materials plays a crucial role in the formation of Rashba-type surface band splitting. Local OAM state in a Bloch wave function produces asymmetric charge distribution (electric dipole). Surface-normal electric field then aligns the electric dipole and results in(More)
We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC). Patients with measurable disease received S-1 orally b.i.d. on days 1-14 and docetaxel intravenously on days 1 and 8 every 3 weeks. In(More)